Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? | SpringerLink
Study design of the EMPEROR-reduced and EMPEROR-preserved trials.... | Download Scientific Diagram
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial | JACC: Heart Failure
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial - Solomon - 2021 - European Journal of Heart Failure - Wiley Online Library
PDF) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum | tctmd.com
European Society of Cardiology on Twitter: "#DELIVER trial: dapagliflozin reduces the risk of #cardiovascular death or worsening #heartfailure in HF patients with mildly reduced and preserved ejection fraction. #ESCCongress https://t.co/QdI8CACYQa ...
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial | Journal of the American College of Cardiology
Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke
Pharmaceutics | Free Full-Text | The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Pooled analysis DAPAHF+DELIVER
EMPEROR-Preserved Trial
DELIVER Trial Scores a Win for Dapagliflozin in HFpEF | tctmd.com
EMPEROR-Preserved: Empagliflozin in HFpEF
ESCCongress: Results of the EMPEROR-Preserved Trial - HealthManagement.org
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Cureus | The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure | Article
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction | Journal of the American College of Cardiology
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial | JACC: Heart Failure
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - Ostrominski - 2022 - European Journal of Heart Failure - Wiley Online Library
